RxDoctor Payments DataLook up a doctor →

Alexandra Deya Quinquilla, MD

Hematology & Oncology · San Juan, PRNPI 1508205121

Payments from drug & device makers

$114,031in general payments, 2019–2025

Across 729 payments — averaging $156.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$97K
  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$2K
  • PBG Puerto Rico LLC$1K
  • Merck$1K
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$16,19396%
  • Education$7434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,031 in reported general payments places this provider in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$402,999
Medicare patients
92
Services billed
10,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib43$714,526
XtandiEnzalutamide46$658,392
PomalystPomalidomide22$500,020
RevlimidLenalidomide23$403,805
SprycelDasatinib21$387,405
TagrissoOsimertinib Mesylate22$364,243
IbrancePalbociclib16$213,889
NinlaroIxazomib Citrate16$206,131
Abiraterone Acetate24$47,021
XgevaDenosumab12$38,195
FulphilaPegfilgrastim-Jmdb13$27,446
Imatinib Mesylate20$11,861
EliquisApixaban13$9,202
Deferasirox14$4,528
Anastrozole191$3,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$2,087$887,42443 claims
Astellas Pharma US IncXtandi$85$658,39246 claims
Bristol Myers SquibbRevlimid$18$403,80523 claims
AstraZenecaTagrisso$1,570$364,24322 claims
PfizerIbrance, Eliquis$97,262$223,09029 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$72$206,13116 claims
AmgenXgeva$1,022$38,19512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →